XLO

Xilio Therapeutics Inc

7.57

Oct 23 • 3:59 PM ET -0.46 (-5.73%)

7.68

Aftermarket • 7:30 PM ET +0.11 (1.45%)

Healthcare Biotechnology USA Nano NASD

Peers: HOWL CTMX CUE JANX NKTR GTBP STTK HCWB IMNN INMB

| Held by: VTI VXF IWC DXUV DCOR DFAC

Scroll to Statements

Index	-
Market Cap	49.81M
Enterprise Value	-79.93M
Income	-21.83M
Sales	64.09M
Book/sh	10.98
Cash/sh	20.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Oct 22, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	0.78
P/B	0.69
P/C	0.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-1.25
Quick Ratio	4.25
Current Ratio	4.25
Debt/Eq	0.09
LT Debt/Eq	0.07
Option/Short	No / Yes

EPS (ttm)	-1.69
EPS next Y	-1.99
EPS next Q	-0.94
EPS this Y	31.26%
EPS next Y	31.08%
EPS next 5Y	10.49%
EPS past 3/5Y	54.70% 31.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	85.65%
Sales Y/Y TTM	327.25%
EPS Q/Q	85.72%
Sales Q/Q	131.22%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	44.07% 46.95%

Insider Own	54.88%
Insider Trans	0.00%
Inst Own	27.39%
Inst Trans	2.12%
ROA	-15.16%
ROE	-55.03%
ROIC	-28.30%
Gross Margin	97.91%
Oper. Margin	-48.94%
Profit Margin	-34.06%
SMA20	-13.88%
SMA50	-15.46%
SMA200	-11.31%
Trades

Shs Outstand	6.58M
Shs Float	2.97M
Short Float	13.81%
Short Ratio	30.47
Short Interest	0.41M
52W High	12.58 -39.85%
52W Low	6.47 17.09%
Volatility	7.50% 4.79%
ATR (14)	0.43
RSI (14)	23.99
Beta	-0.12
Rel Volume	1.21
Avg Volume	13.46K
Volume	16,257

Perf Week	-11.46%
Perf Month	-15.89%
Perf Quarter	-16.72%
Perf Half Y	-8.90%
Perf YTD	-15.54%
Perf Year	-30.06%
Perf 3Y	-71.29%
Perf 5Y	-96.62%
Perf 10Y	-
Recom	1.50
Target Price	18.00
Prev Close	8.03
Price	7.57
Change %	-5.73%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-26	Initiated	Raymond James	Outperform	$16
Aug-06-25	Initiated	Leerink Partners	Outperform	$2
Dec-21-22	Initiated	Chardan Capital Markets	Buy	$7
Jan-10-22	Initiated	H.C. Wainwright	Buy	$36
Nov-16-21	Initiated	Raymond James	Outperform	$31
Nov-16-21	Initiated	Morgan Stanley	Overweight	$32
Nov-16-21	Initiated	Guggenheim	Buy	$40
Nov-16-21	Initiated	Cowen	Outperform

Oct-02-26 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-26 07:30AM	Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-02-26 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-26 07:30AM	Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire)
Jul-06-26 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Jun-29-26 07:30AM	Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer (GlobeNewswire)
May-12-26 07:30AM	Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire)
May-07-26 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-26 04:01PM	Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 (GlobeNewswire)
Apr-16-26 07:30AM	Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors (GlobeNewswire)
Apr-03-26 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-23-26 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-17-26 04:45PM	Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-12-26 08:30AM	Xilio Therapeutics Announces 1-for-14 Reverse Stock Split (GlobeNewswire) -5.31%
Mar-02-26 08:00AM	Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:30AM	Loading…
07:30AM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-26 09:34PM	Xilio Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire) +11.44%
Jan-08-26 08:30AM	Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates (GlobeNewswire)
Nov-13-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.28%
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-12-25 08:25AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-07-25 09:05AM	Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
09:01AM	Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
Nov-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.68% -5.66%
Oct-30-25 09:01AM	Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting (GlobeNewswire)
Oct-03-25 09:00AM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting (GlobeNewswire)
Oct-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-25 07:30AM	Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead (GlobeNewswire) +7.81%
Aug-14-25 08:35AM	Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
09:36AM	Loading…
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-04-25 08:03AM	Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors (GlobeNewswire)
Aug-01-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-28-25 05:05PM	Bristol Myers Squibb and Bain Capital Form New Immunology Company (The Wall Street Journal)
Jul-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-10-25 04:30PM	Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors (GlobeNewswire)
Jun-05-25 06:38PM	Xilio Therapeutics Announces Closing of $50.0 Million Public Offering (GlobeNewswire)
Jun-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 08:46AM	Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering (GlobeNewswire) -34.57%
06:11AM	Xilio Therapeutics Announces Proposed Public Offering (GlobeNewswire)
May-31-25 08:00AM	Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer (GlobeNewswire)
May-08-25 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results (GlobeNewswire) +8.03%
May-02-25 04:30PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-25 04:30PM	Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting (GlobeNewswire) +5.55%
Apr-04-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-25 08:45AM	Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.20%
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 04:30PM	Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.13%
Feb-13-25 04:17AM	AbbVie and Xilio to collaborate on antibody-based immunotherapies (Pharmaceutical Technology) -12.84%
Feb-12-25 10:44AM	Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? (Benzinga) +125.27%
07:35AM	Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs (GlobeNewswire)
07:33AM	AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies (GlobeNewswire)
Feb-03-25 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.30%
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) -29.91%
Jan-21-25 05:05PM	Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer (GlobeNewswire) +11.40%
Jan-17-25 04:30PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-25 05:00PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-24 07:30AM	Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI (GlobeNewswire) +8.25%
Dec-16-24 07:30AM	Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer (GlobeNewswire)
Dec-09-24 09:55AM	After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright (Zacks)
Dec-03-24 04:30PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 09:15AM	Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors (GlobeNewswire) -19.38%
09:05AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:01AM	Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +38.38%
Oct-04-24 09:05AM	Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire) +7.51%
Oct-02-24 04:15PM	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 04:01PM	Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) -10.98%
Aug-08-24 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-13-24 04:05PM	Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors (GlobeNewswire)
May-29-24 06:05AM	Gilead and Cartography enter deal to develop cancer therapies (Pharmaceutical Technology)
May-14-24 01:54PM	XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-16-24 09:14AM	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
Apr-01-24 10:53PM	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-28-24 11:10AM	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60% +7.42%
Jan-31-24 04:01PM	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
Dec-07-23 07:30AM	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data (GlobeNewswire)
Nov-09-23 04:01PM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire) -13.04% -10.62%
Nov-03-23 12:00PM	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors (GlobeNewswire)
Oct-31-23 09:15AM	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting (GlobeNewswire)
Sep-27-23 05:02PM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 08:30AM	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer (GlobeNewswire)
07:30AM	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer (GlobeNewswire)
May-25-23 05:01PM	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors (GlobeNewswire)
May-09-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-03-23 04:05PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.09%
Mar-02-23 04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.37%
Feb-27-23 07:30AM	Xilio Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.72%
Feb-16-23 07:30AM	Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-02-23 07:30AM	Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most (Simply Wall St.)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shannon James Samuel	Director	Mar 26 '26	Buy	8.79	5,000	43,950	10,000	Mar 30 05:29 PM

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Pharm.D.Dr. Rene Russo BCPS

CFO & COOMr. Christopher Frankenfield

Senior Vice President of Finance & AccountingMr. Kevin M. Brennan

Chief Scientific OfficerDr. Uli Bialucha Ph.D.

Chief Information OfficerMr. Nathan McBride

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XLO

Xilio Therapeutics Inc

Upgrade your Finviz experience